|
1
|
Mizrahi JD, Surana R, Valle JW and Shroff
RT: Pancreatic cancer. Lancet. 395:2008–2020. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Viale PH: The American Cancer Society's
facts & figures: 2020 Edition. J Adv Pract Oncol. 11:135–136.
2020.PubMed/NCBI
|
|
4
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ:
Changing profiles of cancer burden worldwide and in China: A
secondary analysis of the global cancer statistics 2020. Chin Med J
(Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Conroy T, Bachet JB, Ayav A, Huguet F,
Lambert A, Caramella C, Maréchal R, Van Laethem JL and Ducreux M:
Current standards and new innovative approaches for treatment of
pancreatic cancer. Eur J Cancer. 57:10–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
National Comprehensive Cancer Network
(NCCN), . Clinical Practice Guidelines in Oncology. Pancreatic
Adenocarcinoma. (v. 1 2022). NCCN; Plymouth Meeting, PA: 2022
|
|
8
|
CSCO, . Guidelines of The Chinese Society
of Clinical Oncology (CSCO) pancreatic cancer 2020. People's
Medical Publishing House; Beijing: 2020
|
|
9
|
Conroy T, Desseigne F, Ychou M, Bouche O,
Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardiere C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cui J, Jiao F, Li Q, Wang Z, Fu D, Liang
J, Liang H, Xia T, Zhang T, Zhang Y, et al: Chinese society of
clinical oncology (CSCO): Clinical guidelines for the diagnosis and
treatment of pancreatic cancer. J National Cancer Center.
2:205–215. 2022. View Article : Google Scholar
|
|
12
|
Oettle H, Riess H, Stieler JM, Heil G,
Schwaner I, Seraphin J, Gorner M, Molle M, Greten TF, Lakner V, et
al: Second-line oxaliplatin, folinic acid, and fluorouracil versus
folinic acid and fluorouracil alone for gemcitabine-refractory
pancreatic cancer: Outcomes from the CONKO-003 trial. J Clin Oncol.
32:2423–2429. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ohba A, Ueno H, Shiba S, Okano N,
Kobayashi T, Nagashima F, Sasahira N, Sasaki M, Imaoka H, Sakamoto
Y, et al: Safety and efficacy of S-IROX (S-1, irinotecan and
oxaliplatin combination therapy) in patients with advanced
pancreatic cancer: A multicenter phase 1b dose-escalation and
dose-expansion clinical trial. Eur J Cancer. 174:40–47. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Go SI, Lee SC, Bae WK, Zang DY, Lee HW,
Jang JS, Ji JH, Kim JH, Park S, Sym SJ, et al: Modified FOLFIRINOX
versus S-1 as second-line chemotherapy in gemcitabine-failed
metastatic pancreatic cancer patients: A randomised controlled
trial (MPACA-3). Eur J Cancer. 157:21–30. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Uesaka K, Boku N, Fukutomi A, Okamura Y,
Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto
H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for
resected pancreatic cancer: A phase 3, open-label, randomised,
non-inferiority trial (JASPAC 01). Lancet. 388:248–257. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okusaka T, Funakoshi A, Furuse J, Boku N,
Yamao K, Ohkawa S and Saito H: A late phase II study of S-1 for
metastatic pancreatic cancer. Cancer Chemother Pharmacol.
61:615–621. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakamura K, Yamaguchi T, Ishihara T, Sudo
K, Kato H and Saisho H: Phase II trial of oral S-1 combined with
gemcitabine in metastatic pancreatic cancer. Br J Cancer.
94:1575–1579. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ueno H, Okusaka T, Furuse J, Yamao K,
Funakoshi A, Boku N, Ohkawa S, Yokosuka O, Tanaka K, Moriyasu F, et
al: Multicenter phase II study of gemcitabine and S-1 combination
therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Jpn J Clin Oncol. 41:953–958. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao Y and Yu X: Comprehensive guidelines
for the diagnosis and treatment of pancreatic cancer (2018
edition). J Clin Hepatol. 34:2109–2120. 2018.
|
|
21
|
Song H, Han B, Park CK, Kim JH, Jeon JY,
Kim IG, Kim HJ, Jung JY, Kim JH, Kwon JH, et al: Phase II trial of
gemcitabine and S-1 for patients with advanced pancreatic cancer.
Cancer Chemother Pharmacol. 72:845–852. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roy V, LaPlant BR, Gross GG, Bane CL and
Palmieri FM; North Central Cancer Treatment Group, : Phase II trial
of weekly nab (nanoparticle albumin-bound)-paclitaxel
(nab-paclitaxel) (Abraxane) in combination with gemcitabine in
patients with metastatic breast cancer (N0531). Ann Oncol.
20:449–453. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schmid P, Adams S, Rugo HS, Schneeweiss A,
Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, et al:
Atezolizumab and Nab-paclitaxel in advanced triple-negative breast
cancer. N Engl J Med. 379:2108–2121. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jotte R, Cappuzzo F, Vynnychenko I,
Stroyakovskiy D, Rodriguez-Abreu D, Hussein M, Soo R, Conter HJ,
Kozuki T, Huang KC, et al: Atezolizumab in combination with
carboplatin and nab-paclitaxel in advanced squamous NSCLC
(IMpower131): Results from a randomized phase III trial. J Thorac
Oncol. 15:1351–1360. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tahara J, Shimizu K, Otsuka N, Akao J,
Takayama Y and Tokushige K: Gemcitabine plus nab-paclitaxel vs.
FOLFIRINOX for patients with advanced pancreatic cancer. Cancer
Chemother Pharmacol. 82:245–250. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Suenaga M, Yamada S, Fujii T, Tanaka C,
Kanda M, Nakayama G, Sugimoto H, Koike M, Fujiwara M and Kodera Y:
S-1 plus nab-paclitaxel is a promising regimen for pancreatic
cancer in a preclinical model. J Surg Oncol. 113:413–419. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li JA, Xu XF, Han X, Fang Y, Shi CY, Jin
DY and Lou WH: Nab-Paclitaxel plus S-1 shows increased antitumor
activity in patient-derived pancreatic cancer xenograft mouse
models. Pancreas. 45:425–433. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang W, Du C, Sun Y, Yang L, Cui C, Jiang
Z, Wang C, Wang J and Zhou A: Nab-paclitaxel plus S-1 as first-line
followed by S-1 maintenance for advanced pancreatic adenocarcinoma:
A single-arm phase II trial. Cancer Chemother Pharmacol.
82:655–660. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi Y, Zhang S, Han Q, Li J, Yan H, Lv Y,
Shi H, Liu R and Dai G: Nab-paclitaxel plus S-1 in advanced
pancreatic adenocarcinoma (NPSPAC): A single arm, single center,
phase II trial. Oncotarget. 8:92401–92410. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dai YH, Yu XJ, Xu HT, Zhuang L, Zhang MS,
Zou YM, Fu Q, Qiu H and Yuan XL: Nab-paclitaxel plus S-1 versus
oxaliplatin plus S-1 as first-line treatment in advanced gastric
cancer: Results of a multicenter, randomized, phase III trial
(GAPSO study). Ther Adv Med Oncol. 14:175883592211180202022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Morimoto M, Toba H, Aoyama M, Nakagawa M,
Takechi H, Yoshida T and Tangoku A: Phase 1 Dose-Escalation study
of triweekly Nab-Paclitaxel combined with S-1 for HER2-Negative
metastatic breast cancer. Clin Breast Cancer. 20:448–453. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The Eighth Edition AJCC Cancer Staging Manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Freites-Martinez A, Santana N,
Arias-Santiago S and Viera A: Using the common terminology criteria
for adverse events (CTCAE-Version 5.0) to evaluate the severity of
adverse events of anticancer therapies. Actas Dermosifiliogr (Engl
Ed). 112:90–92. 2021.(English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu Y, Guo X, Fan Y, Wang D, Wu W, Wu L,
Liu T, Xu B, Feng Y, Wang Y, et al: Efficacy and safety comparison
of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line
chemotherapy for metastatic pancreatic cancer. Jpn J Clin Oncol.
48:535–541. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zong Y, Yuan J, Peng Z, Lu M, Wang X, Shen
L and Zhou J: Nab-paclitaxel plus S-1 versus nab-paclitaxel plus
gemcitabine as first-line chemotherapy in patients with advanced
pancreatic ductal adenocarcinoma: A randomized study. J Cancer Res
Clin Oncol. 147:1529–1536. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim
HY, Choi DW, Kang WK, Park K and Park JO: Impact of epidermal
growth factor receptor (EGFR) kinase mutations, EGFR gene
amplifications, and KRAS mutations on survival of pancreatic
adenocarcinoma. Cancer. 109:1561–1569. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ogura T, Yamao K, Hara K, Mizuno N,
Hijioka S, Imaoka H, Sawaki A, Niwa Y, Tajika M, Kondo S, et al:
Prognostic value of K-ras mutation status and subtypes in
endoscopic ultrasound-guided fine-needle aspiration specimens from
patients with unresectable pancreatic cancer. J Gastroenterol.
48:640–646. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Philip PA, Azar I, Xiu J, Hall MJ,
Hendifar AE, Lou E, Hwang JJ, Gong J, Feldman R, Ellis M, et al:
Molecular characterization of KRAS Wild-type tumors in patients
with pancreatic adenocarcinoma. Clin Cancer Res. 28:2704–2714.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li R, Ng TSC, Wang SJ, Prytyskach M,
Rodell CB, Mikula H, Kohler RH, Garlin MA, Lauffenburger DA,
Parangi S, et al: Therapeutically reprogrammed nutrient signalling
enhances nanoparticulate albumin bound drug uptake and efficacy in
KRAS-mutant cancer. Nat Nanotechnol. 16:830–839. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ueno H, Okusaka T, Ikeda M, Takezako Y and
Morizane C: An early phase II study of S-1 in patients with
metastatic pancreatic cancer. Oncology. 68:171–178. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Haller DG, Cassidy J, Clarke SJ,
Cunningham D, Van Cutsem E, Hoff PM, Rothenberg ML, Saltz LB,
Schmoll HJ, Allegra C, et al: Potential regional differences for
the tolerability profiles of fluoropyrimidines. J Clin Oncol.
26:2118–2123. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chuah B, Goh BC, Lee SC, Soong R, Lau F,
Mulay M, Dinolfo M, Lim SE, Soo R, Furuie T, et al: Comparison of
the pharmacokinetics and pharmacodynamics of S-1 between Caucasian
and East Asian patients. Cancer Sci. 102:478–483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Heggie GD, Sommadossi JP, Cross DS, Huster
WJ and Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and
its metabolites in plasma, urine, and bile. Cancer Res.
47:2203–2206. 1987.PubMed/NCBI
|
